Genta Incorporated said that results of the company's phase III trial of Genasense Injection show that the treatment may enhance the effectiveness of chemotherapy in patients with advanced melanoma.
Subscribe to our email newsletter
Dr Agop Bedikian, the lead author on the paper, said: “This was the first trial to achieve such a broad array of positive endpoints. I believe the aggregate data indicate that Genasense can be a major addition to chemotherapy for patients with this disease, with a side-effect profile that is highly manageable.”
Genasense, Genta's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of resistance to cancer treatment. By knocking down Bcl-2 in cancer cells, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma.